Atlas Trials

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Clinical trial NCT02966093 · COMPLETED

Trial details

NCT number
NCT02966093
Sponsor
Eisai Co., Ltd.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Differentiated Thyroid Cancer (DTC)
Start date
2017-01-11
Primary completion
2019-07-31
Enrollment
151

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.